Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
2.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
3.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH.

J Immunol Methods. 2018 Jul;458:74-82. doi: 10.1016/j.jim.2018.04.007. Epub 2018 Apr 21.

4.

The European Regulatory Environment of RNA-Based Vaccines.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U.

Methods Mol Biol. 2017;1499:203-222. Review.

PMID:
27987152
5.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S.

Cancer Immunol Immunother. 2016 Feb;65(2):161-9. doi: 10.1007/s00262-015-1782-5. Epub 2016 Jan 4.

6.

A framework for T cell assays.

Britten CM, van der Burg SH, Gouttefangeas C.

Oncotarget. 2015 Nov 3;6(34):35143-4. doi: 10.18632/oncotarget.6181. No abstract available.

7.

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28.

8.

Guidelines for the automated evaluation of Elispot assays.

Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A.

Nat Protoc. 2015 Jul;10(7):1098-115. doi: 10.1038/nprot.2015.068. Epub 2015 Jun 25.

PMID:
26110715
9.

Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.

de Witte MA, Kierkels GJ, Straetemans T, Britten CM, Kuball J.

Cancer Immunol Immunother. 2015 Jul;64(7):893-902. doi: 10.1007/s00262-015-1710-8. Epub 2015 May 20. Review.

10.

Generation of TCR-engineered T cells and their use to control the performance of T cell assays.

Bidmon N, Attig S, Rae R, Schröder H, Omokoko TA, Simon P, Kuhn AN, Kreiter S, Sahin U, Gouttefangeas C, van der Burg SH, Britten CM.

J Immunol. 2015 Jun 15;194(12):6177-89. doi: 10.4049/jimmunol.1400958. Epub 2015 May 8.

11.

Thinking outside the gate: single-cell assessments in multiple dimensions.

Kvistborg P, Gouttefangeas C, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJ, Ferrari G, Brinkman RR, Britten CM.

Immunity. 2015 Apr 21;42(4):591-2. doi: 10.1016/j.immuni.2015.04.006. No abstract available.

12.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2015 May;64(5):585-98. doi: 10.1007/s00262-014-1649-1. Epub 2015 Feb 18.

13.

Greater patient access to immuno-oncology therapies-what can policymakers do?

de Lorenzo F, Wait S, Karaca B, Britten CM, van den Bulcke M; European Expert Group on Immuno-Oncology.

Ecancermedicalscience. 2015 Feb 25;9:ed48. doi: 10.3332/ecancer.2015.ed48. eCollection 2015. No abstract available.

14.

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.

Kloke BP, Mahr A, Jabulowsky RA, Kutscher S, Rae R, Britten CM.

Cancer Immunol Immunother. 2015 Jul;64(7):923-30. doi: 10.1007/s00262-014-1643-7. Epub 2014 Dec 30. No abstract available.

PMID:
25548093
15.

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.

Boisguérin V, Castle JC, Loewer M, Diekmann J, Mueller F, Britten CM, Kreiter S, Türeci Ö, Sahin U.

Br J Cancer. 2014 Oct 14;111(8):1469-75. doi: 10.1038/bjc.2013.820. Review.

16.

Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.

Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C.

Cytometry A. 2015 Jan;87(1):37-48. doi: 10.1002/cyto.a.22575. Epub 2014 Oct 8.

17.

Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.

Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Türeci Ö, Sahin U.

Cancer Immunol Res. 2014 Dec;2(12):1230-44. doi: 10.1158/2326-6066.CIR-14-0108. Epub 2014 Sep 22.

18.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.

Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O.

Cancer Immunol Immunother. 2014 Dec;63(12):1273-84. doi: 10.1007/s00262-014-1596-x. Epub 2014 Aug 28.

PMID:
25164876
19.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH.

Cancer Immunol Immunother. 2014 Nov;63(11):1199-211. doi: 10.1007/s00262-014-1593-0. Epub 2014 Aug 19.

20.

Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.

Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, Budden CF, Meeuwenoord NJ, Filippov DV, van der Marel GA, Overkleeft HS, Melief CJ, Ossendorp F.

Cancer Immunol Res. 2014 Aug;2(8):756-64. doi: 10.1158/2326-6066.CIR-13-0223. Epub 2014 Apr 21.

21.

The role of the reporting framework MIATA within current efforts to advance immune monitoring.

Janetzki S, Britten CM; MIATA Core Team.

J Immunol Methods. 2014 Jul;409:6-8. doi: 10.1016/j.jim.2014.05.003. Epub 2014 May 9. No abstract available.

PMID:
24816466
22.

Managing Multi-center Flow Cytometry Data for Immune Monitoring.

White S, Laske K, Welters MJ, Bidmon N, van der Burg SH, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan C.

Cancer Inform. 2015 Jun 10;13(Suppl 7):111-22. doi: 10.4137/CIN.S16346. eCollection 2014.

23.

Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.

Kloke BP, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM.

Cancer Immunol Immunother. 2014 Jul;63(7):749-55. doi: 10.1007/s00262-013-1495-6. Epub 2013 Nov 5. No abstract available.

PMID:
24190545
24.

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U.

Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. No abstract available.

PMID:
24104749
25.

Immunological Monitoring to Rationally Guide AAV Gene Therapy.

Britten CM, Walter S, Janetzki S.

Front Immunol. 2013 Sep 12;4:273. doi: 10.3389/fimmu.2013.00273. Review.

26.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

27.

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples.

Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJ, van der Burg SH, West M, Chan C.

PLoS Comput Biol. 2013;9(7):e1003130. doi: 10.1371/journal.pcbi.1003130. Epub 2013 Jul 11.

28.

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S.

Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319. Epub 2013 Jun 20.

29.

Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.

Kloke BP, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR.

Cancer Immunol Immunother. 2013 May;62(5):975-81. doi: 10.1007/s00262-012-1386-2. Epub 2013 Jan 9. No abstract available.

PMID:
23299564
30.
31.

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM.

Cancer Immunol Immunother. 2013 Apr;62(4):615-27. doi: 10.1007/s00262-012-1359-5. Epub 2012 Nov 9.

32.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

33.

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.

Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2013 Mar;62(3):489-501. doi: 10.1007/s00262-012-1351-0. Epub 2012 Sep 18.

34.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

35.

Harmonization of the intracellular cytokine staining assay.

Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2012 Jul;61(7):967-78. doi: 10.1007/s00262-012-1282-9. Epub 2012 May 22.

36.

Exploiting the mutanome for tumor vaccination.

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn AN, Britten CM, Huber C, Türeci O, Sahin U.

Cancer Res. 2012 Mar 1;72(5):1081-91. doi: 10.1158/0008-5472.CAN-11-3722. Epub 2012 Jan 11.

37.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

38.

Harmonization of immune biomarker assays for clinical studies.

van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.

Sci Transl Med. 2011 Nov 9;3(108):108ps44. doi: 10.1126/scitranslmed.3002785. Review.

PMID:
22072636
39.

Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany.

Hobohm K, Seppmann T, Britten CM, Hoff H.

Cancer Immunol Immunother. 2012 Jan;61(1):137-43. doi: 10.1007/s00262-011-1131-2. Epub 2011 Nov 3. No abstract available.

PMID:
22048716
40.

A methodological framework to enhance the clinical success of cancer immunotherapy.

Hoos A, Britten CM, Huber C, O'Donnell-Tormey J.

Nat Biotechnol. 2011 Oct 13;29(10):867-70. doi: 10.1038/nbt.2000. No abstract available.

PMID:
21997622
41.

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Moodie Z, Price L, Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15.

PMID:
21956511
42.

The impact of harmonization on ELISPOT assay performance.

Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:25-36. doi: 10.1007/978-1-61779-325-7_2.

PMID:
21956498
43.

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.

Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH.

J Transl Med. 2011 Sep 19;9:155. doi: 10.1186/1479-5876-9-155.

44.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group.

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

45.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

46.

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci Ö, Sahin U.

Gene Ther. 2011 Jul;18(7):702-8. doi: 10.1038/gt.2011.17. Epub 2011 Mar 3.

PMID:
21368901
47.

Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop.

Kettner C, Field D, Sansone SA, Taylor C, Aerts J, Binns N, Blake A, Britten CM, de Marco A, Fostel J, Gaudet P, González-Beltrán A, Hardy N, Hellemans J, Hermjakob H, Juty N, Leebens-Mack J, Maguire E, Neumann S, Orchard S, Parkinson H, Piel W, Ranganathan S, Rocca-Serra P, Santarsiero A, Shotton D, Sterk P, Untergasser A, Whetzel PL.

Stand Genomic Sci. 2010 Dec 25;3(3):259-66. doi: 10.4056/sigs.147362.

48.

CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.

Singh SK, Laske K, Gouttefangeas C, Britten CM, Welters MJ.

Cancer Immunol Immunother. 2011 Mar;60(3):443-50. doi: 10.1007/s00262-010-0947-5. Epub 2010 Nov 23. No abstract available.

PMID:
21104411
49.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

50.

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U.

Cancer Res. 2010 Nov 15;70(22):9031-40. doi: 10.1158/0008-5472.CAN-10-0699. Epub 2010 Nov 2.

Supplemental Content

Loading ...
Support Center